Unlike single-pathway compounds, retatrutide simultaneously activates three distinct receptor systems: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors [3]
As of April 15, 2026, it has been removed from the FDA's Category 2 list, with PCAC review scheduled for July 24, 2026 to determine its compounding status
Contact us For More Details: E-mail: [email protected]
How should I store GHRP-6 after mixing
BPC-157 : Derived from a protein in the stomach, BPC-157 promotes healing of muscles, tendons, and ligaments
Originally developed and approved for the management of type 2 diabetes, GLP-1 (glucagon-like peptide-1) receptor agonists have revolutionized the field of obesity medicine